Merck vs Novo Nordisk A S
MRK and NVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRK and NVO compare
Novo Nordisk A S grew revenue faster over the last twelve months (6.4% versus 4.6% for Merck).
Merck pays a dividend yielding 2.3%; Novo Nordisk A S does not pay one.
Merck scores higher on the StockData Score (9 against 4 for Novo Nordisk A S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRK | NVO |
|---|---|---|
| Size and price | ||
| Market cap | $361B | – |
| Share price | $146.33 | $40.00 |
| Change, 1 year | 68.1% | −22.1% |
| Change, 5 years | 79.3% | −29.5% |
| Beta (5Y) | 0.22 | 0.76 |
| Employees | 75K | 70K |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 3 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 117× | – |
| P/S | 5.4× | – |
| P/B | 8.6× | – |
| P/FCF | 22.5× | – |
| PEG | 13.88 | – |
| FCF yield | 4.4% | – |
| Fair value | $42.82 | – |
| Margin of safety | −242% | – |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 6.4% (better) |
| Revenue growth, 5Y average | 9.4% | 19.5% (better) |
| Net income growth (TTM) | −80.7% | – |
| EPS growth (TTM) | −80.7% | 1.8% (better) |
| EPS growth, 5Y average | 21.2% (better) | 20.7% |
| Profitability | ||
| Gross margin | 73.0% | 81.0% (better) |
| Operating margin | – | 41.3% |
| Net margin | 4.8% | – |
| FCF margin | 24.1% (better) | 19.1% |
| Return on equity | 7.0% | – |
| Financial health | ||
| Debt / equity | 1.29 | – |
| Net debt / EBITDA | – | 0.82 |
| Interest coverage | – | 18.8× |
| Current ratio | 1.32 (better) | 0.80 |
| Altman Z-score | 3.74 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | – |
| Payout ratio | 262% | – |
| Years of dividend growth | 15 | – |
| Dividend growth, 5Y average | 5.8% | – |
| Buyback yield | 1.2% | – |
| Shareholder yield | 3.5% | – |
| Ownership | ||
| Held by institutions | 80.3% | 7.3% |
| Held by insiders | 0.05% | 0.00% |
| Insider net buying, 12 months | −$72.0M | – |
| Superinvestors holding | 4 (better) | 1 |
| Short interest, % of float | 1.1% | – |
Go deeper
- MRK stock overview
- MRK income statement
- MRK valuation and score
- NVO stock overview
- NVO income statement
- NVO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.